PMID- 37914901 OWN - NLM STAT- Publisher LR - 20231102 IS - 1573-7241 (Electronic) IS - 0920-3206 (Linking) DP - 2023 Nov 2 TI - Contemporary Medical Management of Peripheral Arterial Disease. LID - 10.1007/s10557-023-07516-2 [doi] AB - PURPOSE: Peripheral arterial disease (PAD) is characterized by atherosclerotic arterial occlusive disease of the lower extremities and is associated with an increased risk of major adverse cardiovascular events (MACE) in addition to disabling clinical sequelae, including intermittent claudication and chronic limb-threatening ischemia (CLTI). Given the growing burden of disease, knowledge of modern practices to prevent MACE and major adverse limb events (MALE) is essential. This review article examines evidence for medical management of PAD and its associated risk factors, as well as wound prevention and care. METHODS: A thorough review of the literature was performed, with attention to evidence for the management of modifiable atherosclerotic risk factors, claudication symptoms, wound prevention, and wound care. RESULTS: Contemporary management of PAD requires a multi-faceted approach to care, with medical optimization of smoking, hypertension, hyperlipidemia, and diabetes mellitus. The use of supervised exercise therapy for intermittent claudication is highlighted. The anatomic disease patterns of smoking and diabetes mellitus are discussed further, and best practices for diabetic foot ulcer prevention, including offloading footwear, are described. Quality wound care is essential in this patient population and involves strategic use of debridement, wound-healing adjuncts, and skin substitutes, when appropriate. CONCLUSION: The objective of medical management of PAD is to reduce the risk of MACE and MALE. Atherosclerotic risk factor optimization, appropriate wound care, and management of diabetic foot ulcers, foot infections, gangrene, and chronic, non-healing wounds are critical components of PAD care. Interdisciplinary care is essential to coordinate care, leverage expertise, and improve outcomes. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Cook, Ian O AU - Cook IO AD - Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, BCM 390, Houston, TX, 77030, USA. FAU - Chung, Jayer AU - Chung J AUID- ORCID: 0000-0001-6404-4414 AD - Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, BCM 390, Houston, TX, 77030, USA. jayer.chung@bcm.edu. LA - eng PT - Journal Article PT - Review DEP - 20231102 PL - United States TA - Cardiovasc Drugs Ther JT - Cardiovascular drugs and therapy JID - 8712220 SB - IM OTO - NOTNLM OT - Chronic limb-threatening ischemia OT - Claudication OT - Critical limb ischemia OT - Foot ulcer OT - Peripheral artery disease OT - Wound care EDAT- 2023/11/02 06:42 MHDA- 2023/11/02 06:42 CRDT- 2023/11/02 00:38 PHST- 2023/10/14 00:00 [accepted] PHST- 2023/11/02 06:42 [medline] PHST- 2023/11/02 06:42 [pubmed] PHST- 2023/11/02 00:38 [entrez] AID - 10.1007/s10557-023-07516-2 [pii] AID - 10.1007/s10557-023-07516-2 [doi] PST - aheadofprint SO - Cardiovasc Drugs Ther. 2023 Nov 2. doi: 10.1007/s10557-023-07516-2.